Circ-ZEB1.33 promotes the proliferation of human HCC by sponging miR-200a-3p and upregulating CDK6

BackgroundAccumulating data indicated that circRNA plays important roles in regulating many biological processes of the tumor, the present study is designated for exploring roles of the circ-ZEB1.33-miR-200a-3p-CDK6 regulating axis in human hepatocellular carcinoma (HCC).MethodsThe regulation axis as predicted by using online tool circNet, the expression and correlation of circ-ZEB1.33-miR-200a-3p-CDK6 was verified in human HCC. The diagnostic value of both tumor and serum circ-ZEB1.33 was estimated by using clinical samples. The roles of circ-ZEB1.33-miR-200a-3p-CDK6 in regulating cell cycle were explored by using in vitro studies.ResultsOverexpression of circ-ZEB1.33 and CDK6, downregulation of miR-200a-3p were detected in human HCC tissues, negative correlation between circ-ZEB1.33 and miR-200a-3p, positive correlation between circ-ZEB1.33 and CDK6 were confirmed in human HCC tissues. Tissue and serum circ-ZEB1.33 were related to different TMN stages and prognosis in HCC patients. RNA pull-down assay implied that circ-ZEB1.33 could decrease miR-200a-3p by sponging miR-200a-3p, and the luciferase reporter assay indicated that miR-200a-3p could downregulate CDK6 transcription by targeting its 3′UTR. The in vitro assays indicated that circ-ZEB1.33 could promote the proliferation of HCC cells by increasing the percentage of S phase regulated by CDK6/Rb.ConclusionProliferation promotion roles of the circ-ZEB1.33-miR-200a-3p-CDK6 regulating axis are existed and verified in human HCC, both tumor and serum circ-ZEB1.33 can serve as an indicator for the prognosis of HCC patients.

[1]  Lei Wang,et al.  Phosphodiesterase 3/4 Inhibitor Zardaverine Exhibits Potent and Selective Antitumor Activity against Hepatocellular Carcinoma Both In Vitro and In Vivo Independently of Phosphodiesterase Inhibition , 2014, PloS one.

[2]  F. Bauzon,et al.  Racing to block tumorigenesis after pRb loss: An innocuous point mutation wins with synthetic lethality , 2010, Cell Cycle.

[3]  Shuwen Han,et al.  Competitive endogenous RNA in colorectal cancer: A systematic review. , 2018, Gene.

[4]  R. Finn,et al.  Treating cancer with selective CDK4/6 inhibitors , 2016, Nature Reviews Clinical Oncology.

[5]  C. Barnett,et al.  Cyclin‐Dependent Kinase Inhibitors for the Treatment of Breast Cancer: Past, Present, and Future , 2016, Pharmacotherapy.

[6]  J. Kjems,et al.  Circular RNAs in cancer: opportunities and challenges in the field , 2017, Oncogene.

[7]  F. Johnson,et al.  Do CDK4/6 inhibitors have potential as targeted therapeutics for squamous cell cancers? , 2017, Expert opinion on investigational drugs.

[8]  Hsien-Da Huang,et al.  CircNet: a database of circular RNAs derived from transcriptome sequencing data , 2015, Nucleic Acids Res..

[9]  H. Burstein,et al.  Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Gil,et al.  Epigenetic regulation of the INK4b-ARF-INK4a locus , 2010, Epigenetics.

[11]  Xi Chen,et al.  Circular RNAs: clinical relevance in cancer , 2017, Oncotarget.

[12]  R. Xu,et al.  Co-expression of XIAP and cyclin D1 complex correlates with a poor prognosis in patients with hepatocellular carcinoma. , 2012, The American journal of pathology.

[13]  K. Coulonval,et al.  Rb inactivation in cell cycle and cancer: The puzzle of highly regulated activating phosphorylation of CDK4 versus constitutively active CDK-activating kinase , 2010, Cell cycle.

[14]  Matthew Ingham,et al.  Cell-Cycle Therapeutics Come of Age. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Qiang Yu,et al.  MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in Metastatic Melanoma. , 2017, The Journal of investigative dermatology.

[16]  G. Shapiro,et al.  Targeting CDK4 and CDK6: From Discovery to Therapy. , 2016, Cancer discovery.